[go: up one dir, main page]

 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (20,240)

Search Parameters:
Keywords = CT

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
4 pages, 722 KiB  
Interesting Images
[89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [18F]PSMA-1007 Imaging
by Moritz B. Bastian, Caroline Burgard, Arne Blickle, Tilman Speicher, Samer Ezziddin and Florian Rosar
Diagnostics 2024, 14(20), 2321; https://doi.org/10.3390/diagnostics14202321 (registering DOI) - 18 Oct 2024
Abstract
We report a case of a 79-year-old male patient with a history of radical prostatectomy for prostate cancer. The patient presented with biochemical reoccurrence; however, previous conventional PSMA PET/CT using [18F]PSMA-1007 showed two indetermined findings with low uptake in the right [...] Read more.
We report a case of a 79-year-old male patient with a history of radical prostatectomy for prostate cancer. The patient presented with biochemical reoccurrence; however, previous conventional PSMA PET/CT using [18F]PSMA-1007 showed two indetermined findings with low uptake in the right iliac lymph nodes. Further MRI evaluation provided no additional information. A recently introduced PSMA tracer, [89Zr]Zr-PSMA-617 (half-life: 3.3 days), was administered in an attempt to confirm the diagnosis and aid in potential radiation planning. [89Zr]Zr-PSMA-617 PET/CT clearly revealed the previously indetermined right iliac lymph nodes as definitely metastatic and also identified additional lymph node metastases that were undetected in prior scans. This case highlights the potential superior sensitivity of [89Zr]Zr-PSMA-617 PET/CT in detecting recurrent disease, especially in unclear settings of [18F]PSMA-1007 PET/CT and demonstrates its potential for guiding targeted radiation therapy with curative intent. Full article
(This article belongs to the Section Medical Imaging and Theranostics)
Show Figures

Figure 1

Figure 1
<p>A 79-year-old male patient with a 23-year history of radical prostatectomy for prostate cancer was referred to our clinic due to biochemical recurrence (BCR), with rising prostate-specific antigen (PSA) levels reaching 0.84 ng/mL. To localize recurrence, we performed a [<sup>18</sup>F]PSMA-1007 PET/CT (<b>A</b>), which revealed two indetermined findings with low uptake (SUV<sub>max</sub> up to 6.4, tumor-to-liver ratio (TLR) 0.39, SUV<sub>mean</sub> liver 16.6) in right iliac lymph nodes potentially suspicious for lymph node metastases. For further evaluation, an MRI of the pelvic region was conducted, but provided no additional constructive information. In an attempt to confirm the diagnosis and aid in potential radiation planning, we opted to administer a novel PSMA PET tracer using long-lived <sup>89</sup>Zr (half-life: 3.3 days), with PET/CT imaging performed 48 h after injection of 147 MBq [<sup>89</sup>Zr]Zr-PSMA-617 (<b>B</b>). The [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT revealed the two right iliac lymph nodes as definitely metastatic with intense uptake (SUV<sub>max</sub> up to 49.5, TLR 12.69, SUV<sub>mean</sub> liver 3.9) and identified additional pelvic and retroperitoneal lymph node metastases (SUV<sub>max</sub> up to 35.1, TLR 9.0, SUV<sub>mean</sub> liver 3.9) that had not been detected on the prior scans. In this case, stereotactic body radiation therapy (SBRT) was the planned treatment following the confirmation of metastatic lymph node involvement.</p>
Full article ">
9 pages, 1294 KiB  
Brief Report
Blood Eosinophils Matter in Post-COVID-19 Pneumonia
by Nicol Bernardinello, Gioele Castelli, Dylan Pasin, Giulia Grisostomi, Marco Cola, Chiara Giraudo, Elisabetta Cocconcelli, Annamaria Cattelan, Paolo Spagnolo and Elisabetta Balestro
Diagnostics 2024, 14(20), 2320; https://doi.org/10.3390/diagnostics14202320 (registering DOI) - 18 Oct 2024
Abstract
Background: Even after the development of vaccines, SARS-CoV-2 continues to cause severe pneumonia all over the world. Consequently, in order to improve the management of patients and optimize the use of resources, predictors of disease severity and lung complications after COVID-19 pneumonia are [...] Read more.
Background: Even after the development of vaccines, SARS-CoV-2 continues to cause severe pneumonia all over the world. Consequently, in order to improve the management of patients and optimize the use of resources, predictors of disease severity and lung complications after COVID-19 pneumonia are urgently needed. Blood cell count is an easily available and reproducible biomarker. With this study, we aimed to explore the role of eosinophils in predicting disease behavior and pulmonary sequelae at first follow-up with computed tomography (CT). Methods: we evaluated blood cell count and other inflammatory markers, both at baseline and during hospitalization, in a large population of hospitalized COVID-19 patients. Results: 327 patients were finally enrolled, 214 were classified as low-intensity medical care (LIMC) and 113 as high-intensity medical care. Eosinophils were higher at discharge in the HIMC group [0.1 (0–0.72) vs. 0.05 (0–0.34) × 109/L; p < 0.0001]. Moreover, in the multivariable analysis, age ≥ 62 years (OR 1.76 (1.05–2.8) p = 0.03) and Δ eosinophils ≥ 0.05 (OR 1.75 (1.05–2.9) p = 0.03) were two independent predictors of residual lung abnormalities in the whole patient population at first follow-up. Conclusions: an eosinophil increase during hospitalization could be a potential predictor of pulmonary sequelae in surviving patients after COVID-19 pneumonia. Full article
(This article belongs to the Special Issue Diagnosis and Management of Thoracic Disease)
Show Figures

Figure 1

Figure 1
<p>Eosinophil trends from admission to hospital discharge in HIMC and LIMC groups. Wilcoxon signed-rank test was used to compare eosinophil values between admission and discharge in HIMC patients (<span class="html-italic">p</span> &lt; 0.0001) and LIMC patients (<span class="html-italic">p</span> &lt; 0.0001). HIMC: high-intensity medical care; LIMC: low-intensity medical care.</p>
Full article ">Figure 2
<p>Example of chest CT scan 3 months after hospital discharge. Panel (<b>A</b>): patient with HIMC and a high rise in eosinophil count with GGO and reticular lung abnormalities (Not-Rec); panel (<b>B</b>): patient with HIMC and a low rise in eosinophil count without residual lung abnormalities (Rec).</p>
Full article ">
11 pages, 1767 KiB  
Review
Botulinum Toxin Treatment of Psoriasis—A Comprehensive Review
by Ali Ghaseminejad-Bandpey, Shahroo Etemadmoghadam and Bahman Jabbari
Toxins 2024, 16(10), 449; https://doi.org/10.3390/toxins16100449 (registering DOI) - 18 Oct 2024
Abstract
A literature search on the subject of botulinum toxin treatment in psoriasis found 15 relevant articles, 11 on human subjects and 4 on animal studies. Of the human data, eight were clinical trials and three were single case reports. Seven out of eight [...] Read more.
A literature search on the subject of botulinum toxin treatment in psoriasis found 15 relevant articles, 11 on human subjects and 4 on animal studies. Of the human data, eight were clinical trials and three were single case reports. Seven out of eight clinical trials, all open-label, reported improvement in psoriasis following intradermal or subcutaneous botulinum toxin injections. One double-blind, placebo-controlled study, which used a smaller dose than the open-label studies, did not note a healing effect. Animal studies have shown that injection of botulinum toxins in the skin heals psoriatic skin lesions and can reduce the level of interleukins (ILs) and cytokines as well as inflammatory cells in psoriatic plaques. There is a need for controlled, blinded studies conducted in larger numbers of patients with doses that have shown promise in open-label studies. Full article
(This article belongs to the Special Issue Botulinum Toxins: New Uses in the Treatment of Diseases (2nd Edition))
Show Figures

Figure 1

Figure 1
<p>Dysregulation of the immune response in psoriasis. From Sieminska et al.—Clin Rev Allergy Immunol 2024 [<a href="#B8-toxins-16-00449" class="html-bibr">8</a>]. Reproduced under creative commons attribution—Courtesy of Springer publisher.</p>
Full article ">Figure 2
<p>Flow chart of human and animal BoNT studies of psoriasis.</p>
Full article ">Figure 3
<p>Injection of BoNTs into the skin inhibits the release of SP and CGRP, thereby attenuating dendritic cell activation and interrupting the downstream inflammatory cascade, ultimately leading to the reduction of keratinocyte hyperproliferation and clinical improvement of psoriatic lesions. Created in BioRender.com with permission.</p>
Full article ">
14 pages, 2780 KiB  
Review
Patellofemoral Instability in the Pediatric and Adolescent Population: From Causes to Treatments
by Anthony Ricciuti, Katelyn Colosi, Kevin Fitzsimmons and Matthew Brown
Children 2024, 11(10), 1261; https://doi.org/10.3390/children11101261 (registering DOI) - 18 Oct 2024
Abstract
Background: Patella instability is one of the most common knee injuries in the adolescent patient. There are several pathoanatomic risk factors which should be assessed via several modalities, including X-rays, magnetic resonance imaging (MRI), or even CT scan. Objectives: We intend to review [...] Read more.
Background: Patella instability is one of the most common knee injuries in the adolescent patient. There are several pathoanatomic risk factors which should be assessed via several modalities, including X-rays, magnetic resonance imaging (MRI), or even CT scan. Objectives: We intend to review these risk factors along with the nonsurgical and surgical techniques used to prevent recurrent dislocations. Methods: We completed an extensive review of the recent literature concerning pediatric and adolescent patellar dislocation and subsequent treatment modalities. Results: We review in detail the risk factors such as patella alta, trochlear dysplasia, lateralization of the tibial tubercle or medialization of the trochlear groove (increased tibial tubercle to trochlear groove (TT–TG) distance), lower limb malalignment, excessive femoral anteversion and/or tibial torsion, and hyperlaxity. There are classification systems for dislocators, and a natural progression of instability that patients often proceed through. Only after a patient has continued to dislocate after bracing and physical therapy is surgical treatment considered. Surgical techniques vary, with the workhorse being the medial patellofemoral ligament (MPFL) reconstruction. However, there are a variety of other techniques which add onto this procedure to address other anatomic risk factors. These include the tibial tubercle osteotomy to address a large TT–TG distance or trochleoplasty to address the lack of a trochlear groove. Conclusions: Nonsurgical and surgical treatments for patella dislocators are tailored to the pathoanatomic risk factors in each patient. Full article
(This article belongs to the Section Pediatric Orthopedics & Sports Medicine)
Show Figures

Figure 1

Figure 1
<p>A 15-year-old with lateral patellar dislocation.</p>
Full article ">Figure 2
<p>Canton Deschamps ratio of 1.5 (38.7/25.7) seen in 14-year-old chronic patellar dislocator.</p>
Full article ">Figure 3
<p>Crossing sign (bold arrow) and supratrochlear spur (thin arrow) seen in lateral XR of 15-year-old patellar dislocator.</p>
Full article ">Figure 4
<p>A15-year-old male with lack of a trochlear groove (arrow points to convex lateral femoral condyle, no groove noted), with laterally subluxated patella.</p>
Full article ">Figure 5
<p>An 11-year-old female with left knee valgus and patellar instability after previous femoral derotation osteotomy and MPFL reconstruction for chronic patellar dislocations.</p>
Full article ">
12 pages, 479 KiB  
Article
18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry
by Paula Estrada, Marta Domínguez-Álvaro, Rafael B. Melero-González, Eugenio de Miguel, Maite Silva-Díaz, Jesús A. Valero, Ismael González, Julio Sánchez-Martín, Javier Narváez, Eva Galíndez, Javier Mendizábal, Carlota L. Iñiguez-Ubiaga, Luis Rodríguez-Rodríguez, Javier Loricera, Alejandro Muñoz, Patricia Moya-Alvarado, Patricia Moran-Álvarez, Vanessa A. Navarro-Ángeles, Carlos Galisteo, Santos Castañeda, Ricardo Blanco and on behalf of ARTESER Project Collaborative Groupadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(20), 6215; https://doi.org/10.3390/jcm13206215 (registering DOI) - 18 Oct 2024
Abstract
Background/Objectives: Imaging studies have transformed the diagnosis of large vessel vasculitis (LVV) involvement in giant cell arteritis (GCA). A positron emission tomography/computed tomography (PET/CT) scan with 18-fluorodeoxyglucose (18F-FDG) has emerged as a valuable tool for assessing LVV. We aimed to determine the utility [...] Read more.
Background/Objectives: Imaging studies have transformed the diagnosis of large vessel vasculitis (LVV) involvement in giant cell arteritis (GCA). A positron emission tomography/computed tomography (PET/CT) scan with 18-fluorodeoxyglucose (18F-FDG) has emerged as a valuable tool for assessing LVV. We aimed to determine the utility of an 18F-FDG-PET/CT scan in detecting LVV in GCA in the ARTESER registry. Methods: The ARTESER study is a large multicenter, retrospective, longitudinal, and observational study, promoted by the Spanish Society of Rheumatology. It included patients newly diagnosed with GCA across 26 tertiary hospitals from 1 June 2013 to 29 March 2019. Patients with a diagnosis of incidental GCA were included if they fulfilled specific criteria, including the ACR 1990 criteria, positive imaging examinations, or the expert clinical opinion of investigators. Differences between patients with positive and negative 18F-FDG-PET/CT scan results were analyzed using a bivariate model. A regression model assessed associations in patients with a positive scan, and the predictive capacity of the cumulative dose of glucocorticoids (GC) on PET scan outcomes was evaluated using ROC curve analysis. Results: Out of 1675 GCA patients included in the registry, 377 met the inclusion criteria of having an 18F-FDG-PET/CT scan. The majority were diagnosed with a cranial GCA phenotype, and 65% had LVV. The thoracic aorta was the most frequently affected. Cardiovascular disease, diabetes, and older age had a negative association with a positive scan outcome. The OR for having a positive 18F-FDG-PET/CTC scan was lower as the number of days increased. Depending on the cumulative dosage of the GC, the 18F-FDG-PET/CT scan showed an AUC of 0.74, with a Youden index > 60 mg/day. Conclusions: Younger patients showed a higher probability of presenting LVV as detected by the 18F-FDG-PET/CT scan. The timing of the examination and the cumulative dosage of the GC influenced the likelihood of a positive result, with earlier tests being more likely to detect inflammation. Full article
(This article belongs to the Special Issue Vasculitis: Current Treatment and Future Options)
Show Figures

Figure 1

Figure 1
<p>Results of the area under curve in the ROC analysis. ROC: receiver operating characteristics. PPV: positive predictive value. NPV: negative predictive value.</p>
Full article ">
14 pages, 1066 KiB  
Article
Using Celery Powder in a Semi-Dry Fermented Sausage ‘Heat-Treated Sucuk’: Nitrosamine Formation, Lipid Oxidation, and Volatile Compounds
by Zeynep Feyza Yılmaz Oral, Mükerrem Kaya and Güzin Kaban
Foods 2024, 13(20), 3306; https://doi.org/10.3390/foods13203306 (registering DOI) - 18 Oct 2024
Abstract
This study investigated the effect of using celery powder (CP) as source of pre-converted nitrite (treatments: A: 150 mg/kg NaNO2, B: 100 mg/kg NaNO2 + CP as 50 mg/kg NaNO2 equivalent, C: 50 mg/kg NaNO2 + CP as [...] Read more.
This study investigated the effect of using celery powder (CP) as source of pre-converted nitrite (treatments: A: 150 mg/kg NaNO2, B: 100 mg/kg NaNO2 + CP as 50 mg/kg NaNO2 equivalent, C: 50 mg/kg NaNO2 + CP as 100 mg/kg NaNO2 equivalent, D: CP as 150 mg/kg NaNO2 equivalent) on the physicochemical and microbiological properties in heat-treated sucuk (HTS), a kind of semi-dry fermented sausage. The influence of cooking time (CT) on the nitrosamine formation in HTS with and without CP was also determined. The results indicated that the use of CP increased the pH value and decreased the aw value. Micrococcus/Staphylococcus and residual nitrite were not affected by the use of CP. TBARS value varied from 0.78 to 0.90 mg MDA/kg. CP did not affect the abundance of hexanal in HTS, however, it increased the abundance of camphene. The results of PCA showed that treatments A, B, and C had similar volatile compound profiles. CP did not affect both N-nitrosodimethylamine and N-nitrosodiethylamine, but their levels increased as the CT increased. Increased CT also resulted in increased N-nitrosopiperidine (NPIP) in all treatments, but the cooking for 1 min did not cause a significant increase in treatments A, B, and C. CP leads to a significant increase in NPIP content, especially after 3 and 5 min of cooking in HTS. Full article
Show Figures

Figure 1

Figure 1
<p>Principal component analysis of the relationships between treatments and volatile compounds. A: 150 mg/kg NaNO<sub>2</sub>, B: 100 mg/kg NaNO<sub>2</sub> + CP as 50 mg/kg NaNO<sub>2</sub> equivalent, C: 50 mg/kg NaNO<sub>2</sub> + CP as 100 mg/kg NaNO<sub>2</sub> equivalent, D: CP as 150 mg/kg NaNO<sub>2</sub> equivalent.</p>
Full article ">Figure 2
<p>The effects of the interaction of using CP and cooking time on the level of NPIP. a–c: Different small letters indicate significant differences between treatments for cooking time. A,B: Different capitals indicate significant differences between cooking times for treatment. A: 150 mg/kg NaNO<sub>2</sub>, B: 100 mg/kg NaNO<sub>2</sub> + CP as 50 mg/kg NaNO<sub>2</sub> equivalent, C: 50 mg/kg NaNO<sub>2</sub> + CP as 100 mg/kg NaNO<sub>2</sub> equivalent, D: CP as 150 mg/kg NaNO<sub>2</sub> equivalent.</p>
Full article ">Figure 3
<p>Cluster analysis of heat map showing the relationship between nitrosamine and treatments cooked at different times.</p>
Full article ">
14 pages, 6105 KiB  
Article
Computed Tomography Anatomy of the Juvenile Cory’s Shearwater (Calonectris borealis) Normal Nasal Cavity
by Alejandro Morales-Espino, Marcos Fumero-Hernández, Francisco Suárez-Cabrera, Mario Encinoso, Magnolia María Conde-Felipe and Jose Raduan Jaber
Animals 2024, 14(20), 3015; https://doi.org/10.3390/ani14203015 (registering DOI) - 18 Oct 2024
Abstract
We conducted a detailed examination of the anterior cranial region of Cory’s Shearwater (Calonectris borealis), employing cutting-edge imaging techniques and computed tomography (CT). The fusion of CT images with anatomical cross-sectional data played a pivotal role in providing a thorough depiction [...] Read more.
We conducted a detailed examination of the anterior cranial region of Cory’s Shearwater (Calonectris borealis), employing cutting-edge imaging techniques and computed tomography (CT). The fusion of CT images with anatomical cross-sectional data played a pivotal role in providing a thorough depiction of the components constituting the anterior cranial region of this species. The explication of these structures holds significant potential as an essential procedure for the prognosis and management of diverse pathologies impacting the nasal cavity of Cory’s Shearwater. Full article
(This article belongs to the Section Wildlife)
Show Figures

Figure 1

Figure 1
<p>Anatomical (<b>A</b>) (labelled with blue lines), sagittal MPR (<b>B</b>) (labelled with an orange line), and horizontal (<b>C</b>) (labelled with a pink line) CT images corresponding to the approximate levels of the respective transverse, sagittal, and dorsal slices of the nasal cavity of a Cory’s Shearwater (<span class="html-italic">Calonectris borealis</span>).</p>
Full article ">Figure 2
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window(<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the beak, corresponding to line I in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. M: maxillary bone; Mb: mandible; mgl: maxillary salivary gland; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>; N: nasal bone; nc: nasal cavity; ns: nasal septum; Oc: oral cavity; Vthn: Ophthalmic division of trigeminal nerve.</p>
Full article ">Figure 3
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the rostral nasal concha, corresponding to line II in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. is: infraorbital sinus; Mb: mandible; mgl: maxillary salivary gland; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>; mpP: maxillary process of palatine bone; N: nasal bone; nc: nasal cavity; ns: nasal septum; Oc: oral cavity; rnc: rostral nasal concha.</p>
Full article ">Figure 4
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the Maxillary salivary gland, corresponding to line III in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. is: infraorbital sinus; Mb: mandible; mgl: maxillary salivary gland; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>; mpP: maxillary process of palatine bone; N: nasal bone; ns: nasal septum; Oc: oral cavity; rnc: rostral nasal concha; Sp: <span class="html-italic">Sinus septalis</span>; T: tongue.</p>
Full article ">Figure 5
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the nasal gland, corresponding to line IV in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. is: infraorbital sinus; Mb: mandible; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>; Mn: <span class="html-italic">Meatus nasalis</span>; mnc: middle nasal concha; mpP: maxillary process of palatine bone; N: nasal bone; nld: nasolacrimal duct; ns: nasal septum; oc: oral cavity; Sp: <span class="html-italic">Sinus septalis</span>; T: tongue.</p>
Full article ">Figure 6
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the infraorbital nerve, corresponding to line V in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. B: beak; cnc: caudal nasal concha; In: infraorbital nerve; is: infraorbital sinus; Mb: mandible; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>. Mn: <span class="html-italic">Meatus nasalis</span>; mnc: middle nasal concha; N: nasal bone; ns: nasal septum; op: oropharynx; Pl: palatine bone; T: tongue.</p>
Full article ">Figure 7
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the medial nasal concha, corresponding to line VI in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. ch: choanal cleft; cnc: caudal nasal concha; is: infraorbital sinus; Mb: mandible; Miv: <span class="html-italic">Musculus intermandibularis ventralis</span>; mnc: middle nasal concha; Mn: <span class="html-italic">Meatus nasalis</span>; N: nasal bone; ns: nasal septum; op: oropharynx; Pl: palatine bone; T: tongue; vs: vascular plexus.</p>
Full article ">Figure 8
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the caudal nasal concha, corresponding to line VII in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. ch: choanal cleft; cnc: caudal nasal concha; Gn: <span class="html-italic">Glandula nasalis</span>; is: infraorbital sinus; Lc: lacrimal bone; Mb: mandible; Mn: <span class="html-italic">Meatus nasalis</span>; N: nasal bone; ns: nasal septum; op: oropharynx; pl: palatine bone; Ptm: pterygoid muscle; T: tongue; v: vomer.</p>
Full article ">Figure 9
<p>Transverse cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the Cory’s Shearwater’s nasal cavity at the level of the <span class="html-italic">bulbus oculi</span>, corresponding to line VIII in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. Bo: <span class="html-italic">bulbus oculi</span>; ch: choanal cleft; cnc: caudal nasal concha; em: extraocular muscle; F: frontal bone; Gn: <span class="html-italic">Glandula nasalis</span>; Hb: hyobranchial apparatus; is: infraorbital sinus; mam: <span class="html-italic">Musculus adductor mandibulae externus</span>; Mb: mandible; Mn: <span class="html-italic">Meatus nasalis</span>; ns: nasal septum; op: oropharynx; pl: palatine bone; Ptm: pterygoide muscle; Tr: trachea; Trm: tracheolateralis muscle; v; vomer.</p>
Full article ">Figure 10
<p>Sagittal cross-section (<b>A</b>), pulmonary window (<b>B</b>), and bone window (<b>C</b>) CT images of the nasal cavity of the Cory’s Shearwater’s. B: beak; Bs: <span class="html-italic">basis cranii</span>; cnc; caudal nasal concha; Cv: <span class="html-italic">camera vitrea bulbi</span>; em: extraocular muscle; F: frontal bone; Mb: mandible; mnc: middle nasal concha; Mx: maxilla; N: nasal bone; Na: nares; on: optic nerve; Pr: parasphenoid rostrum; rnc: rostral nasal concha.</p>
Full article ">Figure 11
<p>Dorsal cross-section (<b>A</b>), pulmonary window (<b>B</b>), and a mix of bone/pulmonary and soft-tissue algorithm (<b>C</b>). CT images of the nasal cavity of the Cory’s Shearwater at the level of the nares corresponding to line IX in <a href="#animals-14-03015-f001" class="html-fig">Figure 1</a>. B: beak; C: <span class="html-italic">Cerebellum</span> (body); cnc: caudal nasal concha; Cv: <span class="html-italic">camera vitrea bulbi</span>; em: extraocular muscle; ie: inner ear; Mae: <span class="html-italic">Meatus acusticus externus</span>; Mn: nasal meatus; mnc: medial nasal concha; ns: nasal septum; On: ocular nerve; rnc: rostral nasal concha.</p>
Full article ">
7 pages, 513 KiB  
Case Report
CT-Derived Patient-Specific Computer Simulation of the Novel Self-Expanding Evolut FX Implantation: A Case Series
by Romy R. M. J. J. Hegeman, Simon E. van Putten, Leo Timmers, Benno J. W. M. Rensing, Uday Sonker, Severin Laengle, Martin Andreas, Martin J. Swaans, Jurriën M. ten Berg and Patrick Klein
J. Clin. Med. 2024, 13(20), 6212; https://doi.org/10.3390/jcm13206212 (registering DOI) - 18 Oct 2024
Abstract
Background/Objectives: Paravalvular leak and permanent pacemaker implantation remain relevant issues after transcatheter aortic valve implantation (TAVI). Novel device development as well as adequate preprocedural device selection can contribute to optimal outcomes. Methods: Computed tomography-based patient-specific computer anatomical analysis and simulation were [...] Read more.
Background/Objectives: Paravalvular leak and permanent pacemaker implantation remain relevant issues after transcatheter aortic valve implantation (TAVI). Novel device development as well as adequate preprocedural device selection can contribute to optimal outcomes. Methods: Computed tomography-based patient-specific computer anatomical analysis and simulation were used in addition to standard preprocedural preparation in three of the first Evolut FX cases in our center. Procedural and follow-up echocardiographic outcomes are presented. Results: Computed tomography-based computer simulation of Evolut FX resulted in implantation of a different size in one of three cases. In three cases of severe aortic valve stenosis, procedural as well as follow-up outcomes were satisfactory and in line with the simulated results of the chosen strategy. Conclusions: Preprocedural patient-specific computer simulation predicts and guides decision-making in TAVI with the Evolut FX platform. The combination of advanced preprocedural technology and novel technologies continues to contribute to the optimization of TAVI outcomes. Full article
(This article belongs to the Special Issue Recent Advances in Transcatheter Aortic Valve Replacement)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>FHG simulation for the three cases of TAVI at high implantation depth with Evolut FX size 26 in the leftmost panel, Evolut FX size 29 in the middle-left panel, and Evolut FX size 34 in the middle-right panel. The rightmost panel shows procedural outcome on aortography.</p>
Full article ">
17 pages, 3974 KiB  
Article
Preparation of Polyvinyl Alcohol–Chitosan Nanocellulose–Biochar Nanosilver Composite Hydrogel and Its Antibacterial Property and Dye Removal Capacity
by Licheng Xie, Zhichao Zhang, Yucai He and Yan Jiang
Processes 2024, 12(10), 2277; https://doi.org/10.3390/pr12102277 (registering DOI) - 18 Oct 2024
Abstract
In this research, silver-loaded biochar (C-Ag) was acquired from a waste fish scale, and nanocellulose (CNF) was prepared from the waste wheat stalk. Then C-Ag was loaded into chitosan-polyvinyl alcohol hydrogel (CTS-PVA) with CNC as a reinforcement agent, and a novel nanocomposite material [...] Read more.
In this research, silver-loaded biochar (C-Ag) was acquired from a waste fish scale, and nanocellulose (CNF) was prepared from the waste wheat stalk. Then C-Ag was loaded into chitosan-polyvinyl alcohol hydrogel (CTS-PVA) with CNC as a reinforcement agent, and a novel nanocomposite material was acquired, which could be efficiently applied for antibacterial and dye removal. By plate diffusion analysis, the inhibition areas of C-Ag-CTS-PVA-CNF (C/CTS/PVA/CNF) hydrogel against E. coli ATCC25922, S. aureus ATCC6538, and P. aeruginosa ATCC9027 could reach 22.5 mm, 22.0 mm, and 24.0 mm, respectively. It was found that the antibacterial rate was 100% in the water antibacterial experiment for 2 h, and the antibacterial activity was more than 90% within 35 days after preparation, and the antibacterial rate was more than 90% after repeated antibacterial tests for five times. Through swelling, water adsorption, water loss rate, and water content tests, the hydrogel manifested good moisturizing properties and could effectually block the loss of water and improve the stability of the C/CTS/PVA/CNF hydrogel. The pseudo-first-order and pseudo-second-order models were built, and the adsorption capacity of hydrogel to dye was analyzed, and the dye removal was more consistent with the pseudo-first-order kinetic model. The best removal effect for Congo red was 96.3 mg/g. The C/CTS/PVA/CNF hydrogel had a remarkable removal efficacy on Malachite green, Methyl orange, Congo red, and Methylene blue. As a result, the C/CTS/PVA/CNF hydrogels had robust antibacterial properties and reusability. In addition, the present research developed a facile strategy for effectual dyes removal from the aqueous medium. Full article
(This article belongs to the Special Issue 2nd Edition of Innovation in Chemical Plant Design)
Show Figures

Figure 1

Figure 1
<p>FT-IR spectra of C/P/F hydrogels, C/P/A hydrogels, C/A/F hydrogels, and C/P/A/F hydrogels.</p>
Full article ">Figure 2
<p>SEM images C/CTS/PVA/CNF hydrogels ×200 (<b>a</b>), ×1000 (<b>b</b>), ×5000 (<b>c</b>), ×30,000 (<b>d</b>).</p>
Full article ">Figure 3
<p>Antibacterial effect of gels prepared from different materials (C/P/F, C/P/A, C/P/F, and C/P/A/F) (<b>a</b>), C–Ag dosage (0.1, 0.5, 1, 2, 3, 4, 5, and 6 g/L) (<b>b</b>), chitosan dosage (10, 12.5, 15, 17.5, 20, and 25 g/L) (<b>c</b>).</p>
Full article ">Figure 4
<p>Antibacterial activity against <span class="html-italic">E. coli</span> (<b>a</b>), <span class="html-italic">S. aureus</span> (<b>b</b>), and <span class="html-italic">P. aeruginosa</span> (<b>c</b>) was observed in C/CTS/PVA/CNF hydrogel composite gel at different dosages (0.5, 1.0, 1.5, 2.0, and 2.5 g/L) and time (0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 h).</p>
Full article ">Figure 5
<p>Antibacterial effect images of C/CTS/PVA/CNF hydrogels prepared on different days (5, 10, 15, 20, 25, 30, and 35 days) (<b>a</b>), repetitive antibacterial properties (1, 2, 3, 4, 5, 6, 7, and 8 times) (<b>b</b>).</p>
Full article ">Figure 6
<p>Synergistic antibacterial mechanism of C/CTS/PVA/CNF hydrogels.</p>
Full article ">Figure 7
<p>Swelling effect (<b>a</b>), water loss (<b>b</b>), moisture adsorption (<b>c</b>), and moisture content (<b>d</b>) images of different CTS dosage (1.0, 1.25, 1.5, 1.75, 2.0, and 2.25 wt%).</p>
Full article ">Figure 8
<p>Kinetic fitting results for methylene blue (MB: 1 g/L) (<b>a</b>), Malachite green (MG: 2.5 g/L) (<b>b</b>), Methyl orange (MO: 1 g/L) (<b>c</b>), and Congo red (CR: 2.5 g/L) (<b>d</b>) adsorption onto C/CTS/PVA/CNF hydrogels.</p>
Full article ">
7 pages, 200 KiB  
Brief Report
The Association Between Rheumatic Disease Therapies and Cardiovascular Outcomes in People with HIV—A Retrospective Cohort Study
by Boghuma K. Titanji, Shumpei Nagatomi, Julia W. Gallini, Xiangqin Cui, Jennifer S. Hanberg, Evelyn Hsieh and Vincent C. Marconi
J. Clin. Med. 2024, 13(20), 6209; https://doi.org/10.3390/jcm13206209 (registering DOI) - 18 Oct 2024
Abstract
Introduction: Inflammation is a significant contributor to cardiovascular disease (CVD) in people with HIV (PWH), who face twice the risk of CVD compared to the general population. The presence of co-existing rheumatic disease (RD) may further exacerbate inflammation and increase the incidence of [...] Read more.
Introduction: Inflammation is a significant contributor to cardiovascular disease (CVD) in people with HIV (PWH), who face twice the risk of CVD compared to the general population. The presence of co-existing rheumatic disease (RD) may further exacerbate inflammation and increase the incidence of CVD events in this population. Methods: We conducted a retrospective cohort study using electronic health record (EHR) data from the Veterans Affairs Medical Center in Atlanta, covering the period from 2000 to 2019. A total of 5000 patients aged 20–87 years who were diagnosed with HIV and receiving care at the Atlanta VAMC between 2000 and 2019 were eligible for this analysis. This study included 3930 veterans with HIV and assessed the impact of rheumatic disease therapies (RDTs) on CVD outcomes. The primary outcome was the first occurrence of a CVD event. Results: Rheumatic disease was significantly associated with an increased risk of CVD events (OR = 2.67; p < 0.001). Additionally, exposure to multiple RDTs (aHR = 2.121, p = 0.047), NSAIDs (aHR = 1.694, p = 0.003), glucocorticoids (aHR = 2.332, p < 0.0001), and hypouricemic agents and colchicine (aHR = 3.445, p < 0.0001) were all significantly associated with increased CVD events. Conclusions: The co-existence of HIV infection and rheumatic disease, along with the use of RDTs, may amplify the risk of CVD events in PWH. These findings underscore the need for further investigation into the relationship between RD, RDTs, and CVD risk in larger, controlled studies, given the potential implications for treatment decisions in this patient population. A limitation of our study is that due to its retrospective design, we could not examine the impact of the sequential use of RDT groups and RD severity on CVD events. Full article
(This article belongs to the Section Epidemiology & Public Health)
14 pages, 1329 KiB  
Article
Extent of Endoscopic Sinus Surgery for Odontogenic Sinusitis of Endodontic Origin with Ethmoid and Frontal Sinus Involvement
by Marta Aleksandra Kwiatkowska, Kornel Szczygielski, Dariusz Jurkiewicz and Piotr Rot
J. Clin. Med. 2024, 13(20), 6204; https://doi.org/10.3390/jcm13206204 (registering DOI) - 18 Oct 2024
Viewed by 101
Abstract
Background/Objectives: Odontogenic sinusitis (ODS) is the most common cause of unilateral maxillary sinus opacification. Initial treatment consists of intranasal steroids and antimicrobial therapy. In case of persistence of the disease, endoscopic sinus surgery (ESS) is advised. It is still not clear what [...] Read more.
Background/Objectives: Odontogenic sinusitis (ODS) is the most common cause of unilateral maxillary sinus opacification. Initial treatment consists of intranasal steroids and antimicrobial therapy. In case of persistence of the disease, endoscopic sinus surgery (ESS) is advised. It is still not clear what extension of ESS is required and whether frontal sinusotomy or ethmoidectomy is justified in ODS with frontal sinus involvement. Methods: Adult patients presented with uncomplicated recalcitrant bacterial ODS due to endodontic-related dental pathology were evaluated by an otolaryngologist and a dentist and scheduled for ESS. Sinus CT scan demonstrated opacification of maxillary sinus and partial or complete opacification of extramaxillary sinuses ipsilateral to the side of ODS. Patients were undergoing either maxillary antrostomy, antroethmoidectomy, or antroethmofrontostomy. Preoperative and postoperative evaluations were done with nasal endoscopy, dental examination, subjective and radiological symptoms. Results: The study group consisted of 30 patients. Statistically significant decreases in values after surgery were found for SNOT-22, OHIP-14, Lund–Mackay, Lund–Kennedy, and Zinreich scale. Tooth pain was present in 40% cases during the first visit and in 10% during the follow-up visit. Foul smell was initially reported by 73.3% and by one patient during follow-up visit (3.3%). Significantly longer total recovery time and more crusting was marked for antroethmofrontostomy when compared to maxillary antrostomy. Conclusions: ESS resolved ODS with ethmoid and frontal involvement in almost every case. Minimal surgery led to improved overall clinical success in the same way as antroethmofrontostomy without risking the frontal recess scarring and stenosis. Full article
Show Figures

Figure 1

Figure 1
<p>Periapical lesion with alveolar bone loss (marked with an asterisk) and total opacification of maxillary sinus (MS) with an extension to the anterior ethmoids visible on coronal CT scan (<b>A</b>) and pus in the middle meatus visible during nasal endoscopy (<b>B</b>); pus marked with a black arrow. NS—nasal septum, MT—middle turbinate, U—uncinate process.</p>
Full article ">Figure 2
<p>SNOT-22, OHIP-14, Lund–Mackay, Lund–Kennedy scale, and Zinreich scale results for each treatment group during the first (v1) and last (v2) otolaryngological visits.</p>
Full article ">Figure 2 Cont.
<p>SNOT-22, OHIP-14, Lund–Mackay, Lund–Kennedy scale, and Zinreich scale results for each treatment group during the first (v1) and last (v2) otolaryngological visits.</p>
Full article ">Figure 3
<p>Total time to resolution in group A, A + E and A + E + F with median, range, and the <span class="html-italic">p</span> value.</p>
Full article ">Figure 4
<p>Comparison between pre- and post-treatment visit groups in different extent of sinus surgery (A—antrostomy, A + E—antroethmoidectomy, A + E + F—antroethmofrontostomy) and <span class="html-italic">p</span>-value for changes in SNOT-22 overall score and Lund-Kennedy overall score.</p>
Full article ">
12 pages, 5452 KiB  
Article
Enhancing Bone Formation Through bFGF-Loaded Mesenchymal Stromal Cell Spheroids During Fracture Healing in Mice
by Kugo Takeda, Hiroki Saito, Shintaro Shoji, Hiroyuki Sekiguchi, Mitsuyoshi Matsumoto, Masanobu Ujihira, Masayuki Miyagi, Gen Inoue, Masashi Takaso and Kentaro Uchida
Bioengineering 2024, 11(10), 1041; https://doi.org/10.3390/bioengineering11101041 (registering DOI) - 18 Oct 2024
Viewed by 106
Abstract
This study aimed to evaluate the osteogenic potential of mesenchymal stromal cell (MSC) spheroids combined with the basic fibroblast growth factor (bFGF) in a mouse femur fracture model. To begin, MSC spheroids were generated, and the expression of key trophic factors (bFGF Bmp2 [...] Read more.
This study aimed to evaluate the osteogenic potential of mesenchymal stromal cell (MSC) spheroids combined with the basic fibroblast growth factor (bFGF) in a mouse femur fracture model. To begin, MSC spheroids were generated, and the expression of key trophic factors (bFGF Bmp2, and Vegfa) was assessed using quantitative PCR (qPCR). A binding assay confirmed the interaction between the bFGF and the spheroids’ extracellular matrix. The spheroid cultures significantly upregulated bFGF, Bmp2, and Vegfa expression compared to the monolayers (p < 0.001), and the binding assay demonstrated effective bFGF binding to the MSC spheroids. Following these in vitro assessments, the mice were divided into five groups for the in vivo study: (1) no treatment (control), (2) spheroids alone, (3) bFGF alone, (4) bFGF-loaded spheroids (bFGF-spheroids), and (5) non-viable (frozen) bFGF-loaded spheroids (bFGF-dSpheroids). Bone formation was analyzed by a micro-CT, measuring the bone volume (BV) and bone mineral content (BMC) of the mice four weeks post-fracture. A high dose of the bFGF (10 µg) significantly promoted bone formation regardless of the presence of spheroids, as evidenced by the increases in BV (bFGF, p = 0.010; bFGF-spheroids, p = 0.006; bFGF-dSpheroids, p = 0.032) and BMC (bFGF, p = 0.023; bFGF-spheroids, p = 0.004; bFGF-dSpheroids, p = 0.014), compared to the controls. In contrast, a low dose of the bFGF (1 µg) combined with the MSC spheroids significantly increased BV and BMC compared to the control (BV, p = 0.012; BMC, p = 0.015), bFGF alone (BV, p = 0.012; BMC, p = 0.008), and spheroid (BV, p < 0.001; BMC, p < 0.001) groups. A low dose of the bFGF alone did not significantly promote bone formation (p > 0.05). The non-viable (frozen) spheroids loaded with a low dose of the bFGF resulted in a higher BV and BMC compared to the spheroids alone (BV, p = 0.003; BMC, p = 0.017), though the effect was less pronounced than in the viable spheroids. These findings demonstrate the synergistic effect of the bFGF and MSC spheroids on bone regeneration. The increased expression of the BMP-2 and VEGF observed in the initial experiments, coupled with the enhanced bone formation in vivo, highlight the therapeutic potential of this combination. Future studies will aim to elucidate the underlying molecular mechanisms and assess the long-term outcomes for bone repair strategies. Full article
Show Figures

Figure 1

Figure 1
<p>Flow cytometric analysis of KUM10 cells. Flow cytometry histograms showing the expression of surface markers in KUM10 cells. The (<b>A</b>) CD45, a pan-leukocyte marker, (<b>B</b>) CD11b, a macrophage marker, and (<b>C</b>) CD31, an endothelial cell marker, all show negative expression in KUM10 cells. In contrast, the mesenchymal stem cell markers (<b>D</b>) Sca1, (<b>E</b>) PDGFR-α, and (<b>F</b>) CD29 show positive expression in KUM10 cells. Blue histograms represent the isotype control, while red histograms represent specific antibody staining.</p>
Full article ">Figure 2
<p>Trophic factor-related gene expression in monolayer- and spheroid-cultured KUM10 cells. (<b>A</b>) Phase-contrast microscopy images of monolayer cells and spheroids. Scale bar indicates 200 μm. (<b>B</b>–<b>D</b>) qPCR analysis results for <span class="html-italic">bFGF</span> (<b>B</b>), <span class="html-italic">Bmp2</span> (<b>C</b>), and <span class="html-italic">Vegfa</span> (<b>D</b>). * indicates <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">Figure 3
<p>Binding assay showing (<b>A</b>) fluorescence microscopy images: scale bar indicates 1 mm. (<b>B</b>) Amount of bFGF bound to the spheroids.</p>
Full article ">Figure 4
<p>Spheroid injection into the fracture site. (<b>A</b>) Spheroid injection into the fracture site using a micropipette. The arrow indicates the fracture line, and the arrowheads point to the injected spheroids. (<b>B</b>) Enlarged view of the area highlighted by the white dashed box in (<b>A</b>). The arrowhead indicates the spheroids. (<b>C</b>) Post-injection image of the fracture site. The arrow indicates the fracture line, and the arrowheads point to the injected spheroids. Scale bar indicates 5 mm.</p>
Full article ">Figure 5
<p>Micro-CT analysis of femurs following transplantation of high-dose bFGF-loaded spheroids. Representative 3D micro-CT images of fractured femurs from the following groups: (<b>A</b>) control, (<b>B</b>) bFGF, (<b>C</b>) Spheroid, (<b>D</b>) bFGF-loaded spheroid (bFGF-spheroid), and (<b>E</b>) bFGF-loaded dead spheroid (bFGF-dSpheroid). (<b>F</b>,<b>G</b>) Quantification of callus area and bone mineral content at the fracture site 4 weeks post-fracture. (<b>F</b>) Analysis of bone volume (mm<sup>3</sup>) in calluses from the control, spheroid, bFGF, bFGF-loaded spheroid (bFGF-spheroid), and bFGF-loaded dead spheroid (bFGF-dSpheroid) groups. (<b>G</b>) Analysis of bone mineral content (mg) in the same groups. Data are presented as mean ± SD (<span class="html-italic">n</span> = 5). “a” indicates statistical significance (<span class="html-italic">p</span> &lt; 0.05) compared to the control group. “b” indicates statistical significance (<span class="html-italic">p</span> &lt; 0.05) compared to the spheroid group.</p>
Full article ">Figure 6
<p>Micro-CT analysis of femurs following transplantation of low-dose bFGF-Loaded spheroids. Representative 3D micro-CT images of fractured femurs from the following groups: (<b>A</b>) control, (<b>B</b>) bFGF, (<b>C</b>) Spheroid, (<b>D</b>) bFGF-loaded spheroid (bFGF-spheroid), and (<b>E</b>) bFGF-loaded dead spheroid (bFGF-dSpheroid). (<b>F</b>,<b>G</b>) Quantification of callus area and bone mineral content at the fracture site 4 weeks post-fracture. (<b>F</b>) Analysis of bone volume (mm<sup>3</sup>) in calluses from the control, spheroid, bFGF, bFGF-loaded spheroid (bFGF-spheroid), and bFGF-loaded dead spheroid (bFGF-dSpheroid) groups. (<b>G</b>) Analysis of bone mineral content (mg) in the same groups. Data are presented as mean ± SD (<span class="html-italic">n</span> = 10). “a” indicates statistical significance (<span class="html-italic">p</span> &lt; 0.05) compared to the control group. “b” indicates statistical significance (<span class="html-italic">p</span> &lt; 0.05) compared to the spheroid group.</p>
Full article ">
16 pages, 1516 KiB  
Article
Association of Ovocalyxin-32 Gene Variants with Egg Quality Traits in Indigenous Chicken Breeds
by Haitham A. Yacoub, Moataz M. Fathi, Ibrahim H. Al-Homidan, Moataz I. Badawy, Mohamed H. Abdelfattah, Mohamed F. Elzarei, Osama K. Abou-Emera and Gamal N. Rayan
Animals 2024, 14(20), 3010; https://doi.org/10.3390/ani14203010 (registering DOI) - 17 Oct 2024
Viewed by 204
Abstract
This study sought to evaluate the genetic variations of the ovocalyxin-32 gene and its association with egg quality traits in indigenous chicken populations, focusing on exons 1 and 6. Genotype frequencies of SNPs (G/T and A/G) within these exons were assessed for their [...] Read more.
This study sought to evaluate the genetic variations of the ovocalyxin-32 gene and its association with egg quality traits in indigenous chicken populations, focusing on exons 1 and 6. Genotype frequencies of SNPs (G/T and A/G) within these exons were assessed for their conformity to the Hardy–Weinberg equilibrium (HWE) across several strains. While most strains exhibited close adherence to HWE expectations, some like light-brown and gray strains indicated substantial discrepancies, particularly for the TT genotype, which points towards the possible effects of genetic drift as well as selection pressures. This study also analyzed the influence of such SNPs on egg quality parameters. A thinner eggshell, reduced shell weight, and decreased breaking strength were associated with the G/T SNP in exon 1, suggesting a likely negative effect on egg quality in T allele carriers. Conversely, the AG genotype displayed better performance in shell thickness, weight and egg weight in the A/G SNP in exon 1, whilst yolk height was best improved by the AA genotype compared to breaking strength. For instance, in exon 6, the A/G SNP enhanced the shell and yolk quality among AG genotypes, while the CC genotype resulted in better eggshell characteristics with enlarged yolks because the C/T SNP was linked. Nonetheless, there were no significant deviations from the HWE despite these associations, which suggested that most breeds had a stable genetic background. Further, considering SNPs’ additive and dominant effects in this research, it was indicated that additive effects account for phenotypic expressions given by the G/T SNP located at exon 1. In contrast, significant additive and dominant effects were observed under the A/G SNP situated at the exon. Generally, it therefore could be concluded from this study that specific SNPs within the ovocalyxin-32 gene may act as good markers for marker-assisted selection (MAS) that can improve desired characteristics—such as those of egg quality—in indigenous chicken breeds. This study demonstrated that both additive and dominance effects must be taken into account when performing genetic analyses, thereby emphasizing the complexity of phenotypic variation caused by genetic mechanisms in native chicken races. Full article
(This article belongs to the Section Animal Genetics and Genomics)
Show Figures

Figure 1

Figure 1
<p>Genotyping of native chicken strains using DNA sequence of C/T SNP of exon 1 of <span class="html-italic">ovocalyxin-32</span> gene. Three different patterns were detected: (<b>a</b>) GG genotype, (<b>b</b>) TT genotype and (<b>c</b>) GT heterozygous. The arrows indicated the mutation position and type.</p>
Full article ">Figure 1 Cont.
<p>Genotyping of native chicken strains using DNA sequence of C/T SNP of exon 1 of <span class="html-italic">ovocalyxin-32</span> gene. Three different patterns were detected: (<b>a</b>) GG genotype, (<b>b</b>) TT genotype and (<b>c</b>) GT heterozygous. The arrows indicated the mutation position and type.</p>
Full article ">Figure 2
<p>Genotyping of native chicken strains using DNA sequence of A/G SNP of exon 1 of <span class="html-italic">ovocalyxin-32</span> gene. Three different genotypes were detected: (<b>a</b>) AA genotype, (<b>b</b>) GG genotype and (<b>c</b>) AG heterozygous. The arrows indicated the mutation position and type.</p>
Full article ">Figure 3
<p>Genotyping of native chicken strains using DNA sequence of A/G SNP of Exon 6 of <span class="html-italic">ovocalyxin-32</span> gene. Three different genotypes were detected: (<b>a</b>) GG genotype, (<b>b</b>) AA genotype and (<b>c</b>) AG heterozygous. The arrows indicated the mutation position and type.</p>
Full article ">Figure 4
<p>Genotyping of native chicken strains using DNA sequence of second SNP of Exon 6 of <span class="html-italic">ovocalyxin-32</span> gene. The three patterns were detected: (<b>a</b>) CC genotype, (<b>b</b>) TT genotype and (<b>c</b>) CT heterozygous. The arrows indicated the mutation position and type.</p>
Full article ">
10 pages, 571 KiB  
Article
Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the Western Australian Context
by Oliver Oey, Chak Pan Lin, Muhammad Adnan Khattak, Thomas Ferguson, Mary Theophilus, Siaw Sze Tiong, Sayed Ali and Yasir Khan
Diseases 2024, 12(10), 257; https://doi.org/10.3390/diseases12100257 (registering DOI) - 17 Oct 2024
Viewed by 222
Abstract
Background: Recent studies have associated total neoadjuvant therapy (TNT) with better treatment adherence, decreased toxicity, improved complete clinical response and anal sphincter preservation rates in patients with locally advanced rectal cancer (LARC). However, real-world experience with TNT in the management of LARC remains [...] Read more.
Background: Recent studies have associated total neoadjuvant therapy (TNT) with better treatment adherence, decreased toxicity, improved complete clinical response and anal sphincter preservation rates in patients with locally advanced rectal cancer (LARC). However, real-world experience with TNT in the management of LARC remains limited. Aim: This study aimed to evaluate the efficacy and safety outcomes of TNT for LARC in Western Australia. Methods: Patients with LARC (cT2-4 and/or cN1-2) who underwent induction chemotherapy followed by neoadjuvant chemoradiotherapy or neoadjuvant chemoradiotherapy followed by consolidation chemotherapy, followed by surgery were recruited from two hospitals in Western Australia. Efficacy outcomes assessed included clinical response (complete, partial, no response), and pathologic complete response (pCR) rate, R0 resection rate, and R1 resection rate were evaluated. Those patients who achieved clinical complete response following TNT were given the option of active surveillance. The safety and tolerability of TNT were assessed. Results: 32 patients with LARC were treated with TNT. In total, 17 patients (53%) received chemoradiotherapy followed by consolidation chemotherapy and 15 patients (47%) received induction chemotherapy followed by chemoradiotherapy. Nine (28%) of the patients with LARC treated with TNT had a complete clinical response, twenty-one (66%) patients had a partial clinical response, and two (6%) patients had no response to TNT. Of the 32 patients, 27 (84%) underwent surgery. There was a 100% R0 resection rate. The pCR rate was 15%. pCR, clinical response, and the R0 resection rate were similar between the two TNT regimens. TNT was well tolerated, with the majority of patients (88%) completing the chemotherapy course with grade 1 and 2 adverse effects. Conclusions: In conclusion, TNT emerges as a promising approach for the management of LARC. However, further research is warranted to refine the optimal TNT protocols, determine its long-term outcomes, and identify patient populations who would benefit the most from this innovative therapeutic strategy. Full article
Show Figures

Figure 1

Figure 1
<p>CONSORT diagram demonstrating the efficacy of TNT.</p>
Full article ">
8 pages, 506 KiB  
Article
A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied?
by Luna van den Brink, Tess Debelle, Lieke Gietelink, Niels Graafland, Annebeth Ruiter, Axel Bex, Harrie P. Beerlage, R. Jeroen A. van Moorselaar, Brunolf Lagerveld and Patricia Zondervan
Cancers 2024, 16(20), 3518; https://doi.org/10.3390/cancers16203518 (registering DOI) - 17 Oct 2024
Viewed by 153
Abstract
Objectives: To determine the rate of benign pathology in cT1 tumors following partial nephrectomy in the Netherlands, thereby evaluating the rate of overtreatment. Methods: Data were collected from a nationwide database containing histopathology of resected renal tissue from 2014 to 2022. Patients [...] Read more.
Objectives: To determine the rate of benign pathology in cT1 tumors following partial nephrectomy in the Netherlands, thereby evaluating the rate of overtreatment. Methods: Data were collected from a nationwide database containing histopathology of resected renal tissue from 2014 to 2022. Patients who underwent partial nephrectomy for suspected RCC staged T1a-b were extracted for analysis. Data are shown in percentages, and multivariable logistic regression was performed to determine predictive factors for benign pathology. Results: 3409 cases were analyzed, of which 403 (12%) were benign and 3006 (88%) malignant. Subtype analysis showed 2126 (62%) cases of clear-cell RCC, followed by 604 (18%) of papillary RCC and 344 (10%) oncocytomas. Mean age was 63 years among patients with malignant pathology versus 65 years for patients with benign lesions (p < 0.001). Mean tumor size was 3.2 cm for malignant pathology and 2.9 cm for benign (p < 0.001). The rates of benign and malignant pathology did not change between 2014 and 2022 (p = 0.377). Multivariable regression showed age ≥ 65 years (65–79 years [OR 1.881, p = 0.002], ≥ 80 years [OR 3.642, p < 0.001]) and tumor size (OR 0.793, p < 0.001) as predictors for benign pathology. The main limitation of this study is that we do not know the biopsy rate of our cohort. Conclusion: This study reports a low rate of 12% benign pathology after partial nephrectomy in the Netherlands. It remains debatable whether these rates are acceptable, or if renal tumor biopsies should be utilized more frequently to reduce overtreatment. Full article
(This article belongs to the Special Issue Optimizing Surgical Procedures and Outcomes in Renal Cancer)
Show Figures

Figure 1

Figure 1
<p>Selection of the study population.</p>
Full article ">
Back to TopTop